Newsletter Tool

Featured Story

FDA orders COVID antibody makers Regeneron, Eli Lilly to track virus variants

By Angus Liu

Emerging coronavirus variants could pose threats to existing monoclonal antibodies and vaccines, and the FDA’s taken note, revising its emergency use authorizations for Eli Lilly’s and Regeneron’s drugs to require monitoring of—and potentially additional testing against—the new variants.

GSK kick-starts phase 3 Medicago-partnered COVID vaccine test

By Ben Adams

GlaxoSmithKline and Sanofi tripped up in a recent COVID-19 vaccine test, but the U.K. Big Pharma is hoping for better luck with its second partner Medicago.

House to vote later this week on bill to delay Medicare sequestration payment cuts

By Robert King

The House plans to vote later this week on legislation to extend a moratorium on Medicare payment cuts installed by sequestration.

AstraZeneca sells hundreds of thousands more doses of COVID-19 antibody combo to U.S. for $205M

By Fraiser Kansteiner

AstraZeneca pledged 500,000 more doses of its experimental COVID-19 antibody drug, AZD7442, to the U.S. on Tuesday, bringing the country's total potential supply up to 700,000 doses in 2021. The government will pay $205 million for the extra stock, lifting the total U.S. investment in the development and supply of the treatment to around $726 million, AstraZeneca said.

Emergent, amid gung-ho COVID-19 production push, eyes upgrade to Canadian vaccine plant: report

By Fraiser Kansteiner

Emergent is in talks with the Canadian government to fund an expansion of its vaccine plant in Winnipeg, The Globe and Mail reports. The facility, which employs around 350, could eventually boast annual capacity for 100 million doses per year.

One year of COVID: Vituity's CMO on how the vaccine changed everything

By Tina Reed

A week after getting his second dose of the COVID-19 vaccine, emergency department physician Gregg Miller and his wife popped a bottle of champagne they'd been saving to mark the occasion. It feels like the beginning of the end of the pandemic, he said.

XPrize names winners of $6M COVID diagnostics competition

By Conor Hale

Nine teams have been selected as the winners of XPrize’s $6 million COVID-19 testing competition, with the goal of providing affordable and accurate diagnostics to help ensure the safety of everyday activities.

Inflammatix nets $102M to advance its immune system tests for infectious diseases